Pharmaniaga Berhad

KLSE:PHARMA Stock Report

Market Cap: RM 511.6m

Pharmaniaga Berhad Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Zulkifli Bin Jafar

Chief executive officer

RM 168.6k

Total compensation

CEO salary percentage83.1%
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1.4yrs
Board average tenure2.6yrs

Recent management updates

Recent updates

Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Jul 18
Pharmaniaga Berhad's (KLSE:PHARMA) Shares Bounce 25% But Its Business Still Trails The Industry

Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

May 09
Why Investors Shouldn't Be Surprised By Pharmaniaga Berhad's (KLSE:PHARMA) Low P/S

Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Apr 19
Pharmaniaga Berhad (KLSE:PHARMA) Shares Could Be 49% Below Their Intrinsic Value Estimate

Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Oct 03
Insufficient Growth At Pharmaniaga Berhad (KLSE:PHARMA) Hampers Share Price

Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Jul 19
Is There An Opportunity With Pharmaniaga Berhad's (KLSE:PHARMA) 37% Undervaluation?

Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Feb 18
Is It Too Late To Consider Buying Pharmaniaga Berhad (KLSE:PHARMA)?

Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Dec 10
Many Would Be Envious Of Pharmaniaga Berhad's (KLSE:PHARMA) Excellent Returns On Capital

Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

Nov 24
Bullish: Analysts Just Made A Massive Upgrade To Their Pharmaniaga Berhad (KLSE:PHARMA) Forecasts

We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

Aug 27
We Think That There Are Issues Underlying Pharmaniaga Berhad's (KLSE:PHARMA) Earnings

CEO Compensation Analysis

How has Zulkifli Bin Jafar's remuneration changed compared to Pharmaniaga Berhad's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

RM 94m

Jun 30 2024n/an/a

-RM 56m

Mar 31 2024n/an/a

-RM 57m

Dec 31 2023RM 169kRM 140k

-RM 80m

Sep 30 2023n/an/a

-RM 689m

Jun 30 2023n/an/a

-RM 654m

Mar 31 2023n/an/a

-RM 655m

Dec 31 2022RM 1mRM 800k

-RM 630m

Sep 30 2022n/an/a

RM 100m

Jun 30 2022n/an/a

RM 164m

Mar 31 2022n/an/a

RM 177m

Dec 31 2021RM 145kn/a

RM 172m

Sep 30 2021n/an/a

RM 80m

Jun 30 2021n/an/a

RM 32m

Mar 31 2021n/an/a

RM 28m

Dec 31 2020RM 61kn/a

RM 27m

Compensation vs Market: Zulkifli's total compensation ($USD37.39K) is below average for companies of similar size in the MY market ($USD107.93K).

Compensation vs Earnings: Zulkifli's compensation has been consistent with company performance over the past year.

CEO

Zulkifli Bin Jafar (52 yo)

less than a year

Tenure

RM 168,569

Compensation

Encik Zulkifli Bin Jafar is the Managing Director at Pharmaniaga Berhad since September 1, 2024 and serves as its Deputy Chief Executive Officer since February 22, 2023 and was its Executive Director since...

Leadership Team

NamePositionTenureCompensationOwnership
Zulkifli Bin Jafar
Deputy CEO & Managing Directorless than a yearRM 168.57kno data
Norai'ni Binti Mohamed Ali
Chief Financial Officer12.5yrsno datano data
Ahmad Shahredzuan Mohd Shariff
COO & Directorless than a yearRM 136.05kno data
Badarulhisam Rahman
Chief Scientific Officer1.9yrsno datano data
Abdul Mohamed
Executive Vice President of Logistics & Distribution Divisionno datano datano data
Zulhazri bin Razali
Executive Vice President of Commercial Divisionno datano datano data
Wan Intan Wan Ismail
Chief Governance Officer & Company Secretary5.1yrsno datano data
Hayat Yahaya
Acting Head of Human Capital Management & Administration Divisionless than a yearno datano data
Idham Ismail
Chief Strategy Officerno datano datano data
Mohd Ishak
Executive Vice President of Manufacturing Divisionless than a yearno datano data
Fazleena Jasin
Head of Sustainabilityno datano datano data
Syaruzaimi Yusof
Company Secretary5.1yrsno datano data

1.4yrs

Average Tenure

52yo

Average Age

Experienced Management: PHARMA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Zulkifli Bin Jafar
Deputy CEO & Managing Directorless than a yearRM 168.57kno data
Ahmad Shahredzuan Mohd Shariff
COO & Director1.8yrsRM 136.05kno data
Ahmad Bakar
President Director of PT Millennium Pharmacon International Tbk4.4yrsno datano data
Yves Champey
Member of Board Advisory Panelno datano datano data
Izaddeen Bin Daud
Non-Independent Director3.8yrsRM 192.81kno data
Mohd Bin Zahur Hussain
Independent Non Executive Directorless than a yearRM 40.00kno data
V. Navaratnam
Member of Board Advisory Panelno datano datano data
Musa bin Mohamad
Chairman of Board Advisory Panelno datano datano data
Piero Olliaro
Member of Board Advisory Panelno datano datano data
Sarah binti Abdul Samat
Independent & Non-Executive Director3.3yrsRM 181.67kno data
Abdul Bin Jaafar
Independent Non Executive Chairmanless than a yearno datano data
Abdul Bin Ahmad
Senior Independent & Non-Executive Director4.1yrsRM 190.04kno data

2.6yrs

Average Tenure

52yo

Average Age

Experienced Board: PHARMA's board of directors are not considered experienced ( 2.6 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 23:09
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharmaniaga Berhad is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hsien Jin LamCGS International
Yee LowHong Leong Investment Bank Berhad
Ping-Khoon ChooKenanga Research